Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
CAPOX BETR 的临床结果和 ctDNA 相关性:一项卡培他滨、奥沙利铂、贝伐珠单抗、曲妥珠单抗治疗既往未接受治疗的晚期 HER2+ 胃食管腺癌的 II 期试验
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-024-51271-3
Singh, Harshabad; Lowder, Kristen E; Kapner, Kevin; Kelly, Ronan J; Zheng, Hui; McCleary, Nadine Jackson; Abrams, Thomas A; Chan, Jennifer A; Regan, Eileen M; Klempner, Samuel J; Hannigan, Alison M; Remland, Joshua; Brais, Lauren K; Andrews, Elizabeth; Yurgelun, Matthew; Cleary, James M; Rubinson, Douglas A; Ritterhouse, Lauren L; Maron, Garrett; Aguirre, Andrew J; Meyerhardt, Jeffrey A; Gardecki, Emma; Lennerz, Jochen K; Wolpin, Brian M; Enzinger, Peter C